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Local treatments for metastases of renal cell carcinoma: 
a systematic review
Saeed Dabestani, Lorenzo Marconi, Fabian Hofmann, Fiona Stewart, Thomas B L Lam, Steven E Canﬁ eld, Michael Staehler, Thomas Powles, 
Börje Ljungberg, Axel Bex
Local treatment of metastases such as metastasectomy or radiotherapy remains controversial in the treatment of 
metastatic renal cell carcinoma. To investigate the beneﬁ ts and harms of various local treatments, we did a systematic 
review of all types of comparative studies on local treatment of metastases from renal cell carcinoma in any organ. 
Interventions included metastasectomy, radiotherapy modalities, and no local treatment. The results suggest that 
patients treated with complete metastasectomy have better survival and symptom control (including pain relief in 
bone metastases) than those treated with either incomplete or no metastasectomy. Nevertheless, the available evidence 
was marred by high risks of bias and confounding across all studies. Although the ﬁ ndings presented here should be 
interpreted with caution, they and the identiﬁ ed gaps in knowledge should provide guidance for clinicians and 
researchers, and directions for further research.
Introduction
Renal cell carcinoma frequently leads to synchronous or 
metachronous metastases1,2 and has an estimated age-
standardised mortality in Europe of 2·6%.3 For synchronous 
metastatic renal cell carcinoma, cyto reductive nephrectomy 
in combination with treatment with interferon alfa resulted 
in a signiﬁ cant improve ment in median overall survival 
compared with treatment with interferon alfa alone.4 
However, in the era of targeted treatment the role of 
cytoreductive nephrectomy is not well deﬁ ned. With 
present targeted drugs, the proportion of patients achieving 
an objective response has been between 20–40%, but 
complete responses were reported in only 1–3% of 
patients.5–7 Data from a population-based analysis suggest 
that median overall survival plateaus at 9–40 months, 
depending on patients’ clinical risk scores.8 Therefore, with 
the exception of rare but durable responses after high-dose 
interleukin 2, removal of all synchronous or metachronous 
lesions, when technically feasible and clinically appropriate, 
provides the only potentially curative treatment alternative. 
However, the beneﬁ ts of local therapeutic options for 
metastases from renal cell carcinoma are controversial. 
Despite retrospective data suggesting consistently that 
complete resection of solitary or oligometastatic metastatic 
renal cell carcinoma suggests a favourable prognosis 
independent of race or geographical location,9 uncertainty 
exists as to whether this is because of favourable tumour 
biology, the role of metastasectomy, or both. Less disputed 
beneﬁ ts of complete resection include symptom palliation, 
and delay or withdrawal of systemic treatment, thereby 
avoiding associated toxicities.
Metastases from renal cell carcinoma are common in 
lung, bone, liver, and brain, but can occur at any 
anatomical site.10,11 Surgical resection is a possible 
treatment for these metastases, but metastases’ 
accessibility and resectability, and patients’ performance 
and comorbidities have to be taken into account.12 
Radiotherapy modalities can provide valid local non-
invasive treatment alternatives to surgery. For brain 
metastases, these include whole-brain radiotherapy 
(WBRT) or stereotactic radiosurgery (SRS). By contrast 
with WBRT, SRS delivers highly collimated radiation to a 
precisely deﬁ ned target area, minimising the radiation 
dose to surrounding areas.13 For other sites, including 
bone, conventional radiotherapy (CRT) or stereotactic 
body radiotherapy (SBRT) are options. CRT is fractionated 
radiotherapy primarily applied to treat painful metastases, 
whereas SBRT, like SRS, delivers high-dose single-fraction 
or multi-fraction radiation.14
Until now, no systematic review on the outcome 
of diﬀ erent local treatment options for metastases from 
renal cell carcinoma has been done, and there is a need to 
identify potential beneﬁ ts of such an approach. There-
fore, in this systematic review, we aimed to address the 
question of whether integration of local treatment of 
metastases into the management of metastatic renal cell 
carcinoma is beneﬁ cial and, if so, what the best treatment 
modalities are.
Search strategy and selection criteria
The review was done according to Preferred Reporting 
Items for Systematic reviews and Meta-Analyses 
(PRISMA) guidelines,15 and in accordance with the 
principles outlined in the Cochrane Handbook for 
Systematic Reviews of Interventions.16 Studies were 
identiﬁ ed by searching electronic databases and relevant 
websites. Sensitive electronic searches were done to 
identify reports of randomised controlled trials or non-
randomised comparative studies of local treatment for 
metastatic renal cell carcinoma. The search strategy 
excluded studies published before Jan 1, 2000, and there 
were no language restrictions. We searched Medline 
(January, 1946, to Sept 30, 2013), Medline In-Process 
(from inception up to Sept 30, 2013), Embase (January, 
1974, to Sept 30, 2013), Cochrane Central Register of 
Controlled Trials (The Cochrane Library, Issue 8, 2013), 
and Latin American and Caribbean Center on Health 
Sciences Information (from January 1967, to Sept 30, 
2013). Additional reports were identiﬁ ed through 
searches of the reference lists of included studies and by 
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an expert panel (European Association of Urology Renal 
Cell Carcinoma Guideline Panel). The search strategy 
has been described elsewhere;17 the present Review 
represents an update of the original search.
Only comparative studies were included, including 
randomised controlled trials, prospective non-randomised 
comparative interventional studies, prospective obser-
vational studies with a comparator arm, and retro spective 
comparative studies. Studies with no comparator group 
(eg, single-arm case series), non-eﬀ ectiveness studies 
(eg, prognostication or nomogram studies), reviews, or 
studies with fewer than ten patients per group were 
excluded, as were reviews, basic science studies, genetic 
or epidemiological studies, case series or case reports, 
studies of local recurrence only, studies of tumour 
thrombosis of the vena cava, studies of experi mental 
treatments, studies of systemic treatment only, and 
studies examining only localised treatments for primary 
kidney cancer. Some of these excluded studies were 
retained for discussion, to give clinical context as to the 
relevance and implication of the review ﬁ ndings.
The patient population assessed included patients with 
metastatic renal cell carcinoma to any organ, except those 
with synchronous metastases to the ipsilateral adrenal 
gland or retroperitoneal lymph nodes only. There were 
no restrictions regarding previous treatment with 
cytoreductive nephrectomy or systemic or targeted 
treatment. The types of interventions included metasta-
sectomy with or without intended complete resection of 
metastases in any organ, WBRT, CRT, SRS, SBRT, 
CyberKnife radiotherapy, hypofractionated radiotherapy, 
and no local treatment. The primary outcomes assessed 
were overall survival, cancer-speciﬁ c survival, and 
progression-free survival. Local tumour control, quality of 
life, symptom control, and adverse events or toxic eﬀ ects 
were assessed as secondary outcomes.
Two reviewers (SD and LM) independently screened 
titles and abstracts of all references identiﬁ ed by the 
search strategies. Full text copies of all potentially 
relevant reports were obtained and independently 
assessed by two reviewers (SD and LM) to identify 
whether they met the predeﬁ ned inclusion criteria. Any 
disagreements were resolved by consensus or 
arbitration by a third person (TBLL). A data extraction 
form was developed speciﬁ cally for the purpose of this 
assessment to collect information on study design, 
characteristics of participants, character istics of inter-
ventions, and outcome measures. Two reviewers 
(SD and LM) independently assessed the risk of bias 
of individual studies. The standard Cochrane 
Collaboration risk of bias instrument16 was used to 
assess the risk of bias in randomised controlled trials, 
whereas for non-randomised comparative studies the 
risk of bias instrument recommended by the Cochrane 
Non-Randomised Studies Methods Group was used.16 
Additionally, for non-randomised comparative studies, 
the main confounders for the primary outcomes 
(ie, survival or tumour response) were identiﬁ ed a 
priori by the expert panel. The main confounders 
identiﬁ ed were age, sex, Fuhrman grade, size or volume 
of metastases, previous treatment before local 
treatment, performance status, treatment of diﬀ erent 
sites in the same study, and tumour histology. The 
confounders were assessed for the following four 
criteria: ﬁ rst, whether the confounder was considered 
by the study author; second, the precision of 
measurement; third, if there was a baseline imbalance 
between the intervention and comparator group or 
groups; and ﬁ nally, the quality of adjustment for 
imbalance in studies with various treatment sites.18 
A study was regarded as at high risk of bias, if any of 
the confounders were imbalanced between 
experimental groups. For outcomes in which the data 
synthesis involved randomised control trials, or non-
randomised comparative studies with low risk of bias, 
the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE)19 was used to 
assess the quality of evidence.
For data analysis, descriptive statistics were used to 
summarise baseline characteristics. A quantitative 
synthesis (ie, meta-analysis) was planned for 
randomised controlled trials only, because of the 
inherent clinical and methodological heterogeneity 
present in non-randomised studies. When pooling of 
data was not done, and where appropriate, results were 
presented in forest plots to allow a visual comparison of 
the eﬀ ects of interventions between studies. Both ﬁ xed-
eﬀ ects and random-eﬀ ects models were used to derive 
Figure 1: PRISMA ﬂ ow diagram
2180 abstracts and titles screened
1991 records excluded
189 articles identiﬁed for full text screening
189 articles full text screened
173 full text articles excluded
16 studies included in systematic review
Treatment site
   8 various 
    1 lung
   3 bone
   2 brain
   1 liver
    1 pancreas
95 abstracts identiﬁed from other sources2085 abstracts and titles identiﬁed through
            database searching
34 studies retained for 
      discussion
www.thelancet.com/oncology   Vol 15   November 2014 e551
Review
the appropriate test statistic. For time-to-event data, 
hazard ratios and 95% CIs obtained directly from 
studies or indirectly from presented Kaplan-Meier 
survival curves were used to compare results.20 In 
analysing dichotomous outcomes, relative risks with 
95% CIs were used, whereas for continuous outcomes, 
means and SDs or medians and ranges were used to 
summarise the data, and weighted mean diﬀ erences 
and 95% CIs were used to compare interventions. 
Statistical heterogeneity between studies was assessed 
by visual inspection of plots of the data, the χ² test for 
heterogeneity, and the I² statistic.21 Analyses were done 
using Cochrane RevMan version 5.2. If a meta-analysis 
was not feasible, a narrative synthesis was provided.22
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Findings
The literature search identiﬁ ed 2180 studies, 189 of which 
were selected for full-text screening (ﬁ gure 1). Six articles 
in languages other than English were translated. 
16 studies reporting on 2350 patients were eligible for 
ﬁ nal inclusion. Of studies not meeting the inclusion 
criteria, 34 were retained for discussion.
All 16 included studies were retrospective comparative 
studies (table 1). No randomised controlled trials or 
prospective non-randomised comparative studies were 
identiﬁ ed. Eight studies assessed local treatments of 
metastases from renal cell carcinoma in various 
organs,12,24,26,27,29–32 of which the most common sites were lung, 
bone, liver, and brain, and less common sites were pancreas, 
adrenal gland, lymph nodes, thyroid gland, spleen, ethmoid 
sinus, and skin (table 1). Other studies also assessed local 
treatments for metastases from renal cell carcinoma in bone 
(including the vertebrae),33–35 the brain,36,37 liver,25 lung,23 and 
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Adj=adjuvant. CN=cytoreductive nephrectomy. CRT=conventional radiotherapy. CSS=cancer-speciﬁ c survival. ECOG=Eastern Cooperative Oncology Group performance status. FSRT=fractionated stereotactic 
radiotherapy. IGRT=image-guided radiotherapy. KS=Karnofsky performance status. MSKCC=Memorial Sloan Kettering Cancer Center. MTS=metastasectomy. NR=not reported. OS=overall survival. 
PFS=progression-free survival. RN=radical nephrectomy. RPA=recursive partition analysis. SBRT=single-fraction high-dose stereotactic body radiation therapy. SRS=stereotactic radiosurgery. SysT=systemic 
therapy. WBRT=whole-brain radiotherapy.
Table 1: Baseline characteristics of all included studies
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Comparator Outcome p value
Amiraliev et al (2012)23 (abstract only; lung)
Immunotherapy (interferon alfa; n=41) Complete metastasectomy (n=90) Median OS 18·0 vs 36·3 months <0·05
Targeted therapy (sunitinib + sorafenib; n=21) Complete metastasectomy (n=90) Median OS 30·4 vs 36·3 months <0·05
Notes Three-arm study. Not reported if systemic therapy 
was given to metastasectomy group
Alt et al (2011)12 (various: 39% lung only, 40% lung + various)
Incomplete metastasectomy (n=762) Complete metastasectomy (n=125) Median OS 15·6 vs 48·0 months, adjusted HR 2·61 
(95% CI 1·99–3·42). Median CSS 15·6 vs 57·6 months, 
adjusted HR 2·91 (2·17–3·90)
OS <0·001; CSS <0·001
Notes Type of systemic therapy not speciﬁ ed in study. 
43·7% of all patients also received radiation therapy 
for ≥1 metastases
Petralia et al (2010)24 (abstract only; various [% lung NR])
Incomplete metastasectomy, no metastasectomy, 
or systemic therapy (n=143)
Complete metastasectomy (n=35) Median CSS 14 vs 30 months, adjusted HR 1·71 
(95% CI 1·09–2·69)
0·02
Notes Type of systemic therapy given not speciﬁ ed in study
Staehler et al (2010)25 (liver)
No metastasectomy (refused surgery; n=20) Complete metastasectomy (n=68) Median OS 27 vs 142 months, adjusted HR 2·23 
(95% CI 1·05–4·72)
0·003
Notes Adjuvant systemic therapy was interferon alfa, 
interleukin 2, or both. 6% of patients received 
multikinase inhibitors
Staehler et al (2009)26 (abstract only; various [67% lung])
No metastasectomy (refused surgery; n=183) Complete metastasectomy (n=57) Mean OS at 5 years 35·3% (SD 9·2) vs 57·8% (5·9)




Notes Author contacted to get study data. Median OS and 
OS HR based on statistical analysis of acquired data. 
Not reported if systemic therapy was given
Eggener et al (2008)27 (various [64% lung])
No metastasectomy (n=85) Metastasectomy (91% complete; n=44) Median OS 21 vs 45 months, adjusted HR 2·70 
(95% CI 1·6–4·5)
<0·001
Notes Not reported if systemic therapy was given
Zerbi et al (2008)28 (pancreas)
No metastasectomy (n=13) Complete metastasectomy (n=23) OS at 2 years 59% vs 95% (p value NR); OS at 5 years 47% 
vs 88% (p value NR). Median survival for complete 
metastasectomy not reached; median survival for no 
metastasectomy 27 months (95% CI 17·5–50·2)
Median survival 0·0263
Notes Adjuvant systemic therapy was interferon alfa, 
interleukin 2, or both. 5·5% of patients also received 
thalidomide
Brinkmann et al (2007)29 (various [85% lung])
No metastasectomy (n=18) Complete metastasectomy (n=16) Median CSS 50 (range 18–104) vs 58 months (9–104) 0·223
Notes Neoadjuvant systemic therapy was a combination of 
interferon alfa, interleukin 2, and ﬂ ourouracil
Kwak et al (2007)30 (various [48% lung])
No metastasectomy (n=41) Complete metastasectomy (n=21) Median OS 8·4 vs 36·5 months, adjusted HR 2·57 
(95% CI 1·21–5·44)
<0·001
Notes Study only included patients who had not 
received any immunotherapy
Russo et al (2007)31 (various [48% lung])
No metastasectomy or incomplete 
metastasectomy (n=30)
Complete metastasectomy (n=61) Median OS 12 vs 30 months NR
Notes Not reported if systemic therapy was given
Lee et al (2006)32 (various [63% lung])
No metastasectomy + systemic therapy (n=37) Metastasectomy (45% complete) + systemic therapy 
(n=20)
Median CSS 13 vs 23 months. Median PFS 5 vs 13 months CSS 0·11; PFS 0·0226
(Table 2 continues on next page)
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Comparator Outcome p value
(Continued from previous page)
Incomplete metastasectomy + systemic therapy 
(n=11)
Complete metastasectomy + systemic therapy (n=9) Median CSS 20 vs 28 months (unadjusted HR 3·47, 
95% CI 1·26–9·56)
0·016
Notes Adjuvant systemic therapy was a combination of 
interferon alfa, interleukin 2, and ﬂ ourouracil. HR was 
only available for incomplete metastasectomy 
subgroup vs complete metastasectomy subgroup
Zelefsky et al (2012)33 (bone [various locations])
Single-dose IGRT ≥24 Gy/dose (n=45) Hypofractionated IGRT (n=46) Local PFS at 3 years 88% vs 17% 0·001
Single-dose IGRT (n=59) Hypofractionated IGRT (n=46) Local PFS adjusted HR 0·28 (95% CI 0·11–0·72) 0·008
Notes HR for PFS is for all participants in intervention arm. 
Not reported if systemic therapy was given
Hunter et al (2012)34 (bone [spine C1 to sacrum])
CRT (n=34) Single-dose SBRT (n=76) Pain relief ORR 68% vs 62%, unadjusted HR 1·28 
(95% CI 0·78–2·08)
0·67
CRT (n=34) Single-dose SBRT (n=76) Median time to pain relief 0·6 vs 1·2 weeks 0·29
CRT (n=25) Single-dose SBRT (n=54) Median duration of pain relief 1·7 vs 4·8 months (n=54) 0·095
Notes Not reported if systemic therapy was given. Unclear 
amount of metastatic burden
Fuchs et al (2005)35 (bone [various locations])
Metastasectomy and local stabilisation (n=33) Non-surgical treatment (n=27) 5-year CSS 36% vs 8% 0·0066
Notes Type of systemic therapy given only stated as 
chemotherapy. 82% of all patients also received 
radiation therapy for metastases
Fokas et al (2010)36 (brain)
SRS (n=51) WBRT (n=20) OS at 2 years 40% vs 0% <0·001
SRS + WBRT (n=17) WBRT (n=20) OS at 2 years 35% vs 0% <0·001
SRS (n=51) SRS + WBRT (n=17) OS at 2 years 40% vs 35% 0·703
SRS RPA class I (n=17) SRS + WBRT RPA class I (n=3) OS at 2 years 52% vs 60% <0·001
SRS RPA class II–III (n=34) WBRT RPA class II–III (n=20) OS at 2 years 24% vs 0% <0·001
SRS RPA class II–III (n=34) SRS + WBRT RPA class II–III (n=14) OS at 2 years 24% vs 21% <0·001
SRS + WBRT class II–III (n=14) WBRT RPA class II–III (n=20) OS at 2 years 21% vs 0% <0·001
SRS (n=51) WBRT (n=20) Intracerebral control at 2 years 38% vs 0% <0·001
SRS + WBRT (n=17) WBRT (n=20) Intracerebral control at 2 years 29% vs 0% <0·001
SRS (n=51) SRS + WBRT (n=17) Intracerebral control at 2 years 38% vs 29% 0·032
SRS RPA class I (n=17) SRS + WBRT RPA class I (n=3) Intracerebral control at 2 years 59% vs 100% <0·001
SRS RPA class II–III (n=34) WBRT RPA class II–III (n=20) Intracerebral control at 2 years 27% vs 0% <0·001
SRS (n=34) RPA class II–III SRS + WBRT RPA class II–III (n=14) Intracerebral control at 2 years 27% vs 21% <0·001
SRS + WBRT class II–III (n=14) WBRT RPA class II–III (n=20) Intracerebral control at 2 years 21% vs 0% <0·001
Notes Three-arm study. OS and intracerebral control 
outcomes for SRS or SRS + WBRT vs WBRT alone for 
RPA class I not in table because the WBRT subgroup 
for RPA class I=0 patients. No speciﬁ c deﬁ nition of 
symptom control given. Not reported if systemic 
therapy was given
Ikushima et al (2000)37 (brain)
FSRT (n=10) Metastasectomy + CRT (n=11) and CRT alone (n=12) CSS at 1 year 90% vs 64% and 25%. CSS at 2 years 54% vs 27% 
and 17%. CSS at 3 years 41% vs 9% and 8%
NR
FSRT (n=10) Metastasectomy + CRT (n=6) 2-year LC 55·2% vs 70·0% 0·61
FSRT (n=10) CRT alone (n=4) 2-year LC 55·2% vs NR NR
Notes Three-arm study. Actuarial LC rates only for 
patients who were followed up by imaging studies. 
Not reported if systemic therapy was given
CRT=conventional radiotherapy. CSS=cancer-speciﬁ c survival. FSRT=fractionated stereotactic radiotherapy. HR=hazard ratio. IGRT=image-guided radiotherapy. LC=local control. NR=not reported. ORR=overall 
response rate (complete pain relief response and partial pain relief response in total). OS=overall survival. PFS=progression-free survival. RPA=recursive partitioning analysis. SBRT=Single-fraction high-dose 
stereotactic body radiation therapy. SRS=stereotactic radiosurgery. WBRT=whole-body radiotherapy. 
Table 2: Summary of results regarding comparative eﬀ ectiveness and harms of all included studies
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pancreas (table 1).28 Three studies23,24,26 were abstracts only 
(table 1). The heterogeneity of data did not allow for a meta-
analysis; a narrative synthesis of the evidence is presented 
instead. There was great variation in the type and distribution 
of systemic treatments and in their reporting across studies. 
Generally, systemic treatment consisted of cytokines and 
VEGF inhibitors. Eight studies23,26,27,31,33,34,36,37 contained no 
information on whether systemic treatment was given; three 
studies12,24,35 did not specify the type of systemic treatment. 
Three studies25,28,32 used treatment after metastasectomy and 
one study29 used treatment beforehand. In one study,30 
systemic treatment was not used.
Complete versus no or incomplete metastasectomy
All of the eight studies12,24,26,27,29–32 that assessed metastases 
from renal cell carcinoma in various organs reported on 
complete metastasectomy versus no metastasectomy, 
incomplete metastasectomy, or both (table 2). However, 
in one study,32 complete resection was achieved in only 
45% of the metastasectomy group, which was compared 
with patients with no metastasectomy. No other focal 
treatment modalities were applied. In six of the eight 
studies,12,24,26,27,30,32 a signiﬁ cantly longer median overall 
survival or cancer-speciﬁ c survival was reported after 
complete metastasectomy compared with incomplete or 
no metastasectomy (median of medians overall survival 
or cancer-speciﬁ c survival 40·8 months, IQR 31·6–48·0), 
or both (14·8 months, 13·3–21·0). Of the two remaining 
studies, in one29 there was no signiﬁ cant diﬀ erence in 
cancer-speciﬁ c survival between complete metastasectomy 
and no metastasectomy (58 vs 50 months; p=0·223); 
however, only 18 and 16 patients were assessed in the 
respective study groups. In the other study31 there was a 
numerically longer median overall survival for the 
metastasectomy group (30 vs 12 months), but the p value 
was not provided. A forest plot of hazard ratios for overall 
survival or cancer-speciﬁ c survival in studies in which 
incomplete or no metastasectomy was compared with 
complete metastasectomy for metastatic renal cell 
carcinoma to various organs shows improved overall 
survival and cancer-speciﬁ c survival for complete 
metastasectomy (ﬁ gure 2).
Regarding metastasectomy in speciﬁ c organs, three 
studies assessed metastases to lung,23 liver,25 and 
pancreas (table 2).28 In the lung study,23 there was 
signiﬁ cantly higher median overall survival after meta-
stasectomy compared with both targeted treatment and 
immunotherapy (36·3 vs 30·4 and 18·0 months, 
respectively, p<0·05). In the liver study,25 median 
overall survival was signiﬁ cantly higher for meta-
stasectomy compared with no metastasectomy 
(142 months [95% CI 115–169] vs 27 months [16–38]; 
p=0·003). In the pancreas study,28 5-year overall 
survival was numerically higher for metastasectomy 
compared with no metastasectomy (88% vs 47%). 
Median overall survival was signiﬁ cantly longer for 
metastasectomy (p=0·0263; table 2).
Three studies on local treatments for bone metastases 
were identiﬁ ed (table 2). In one study,33 single-dose 
image-guided radiotherapy (IGRT) was compared with 
hypofractionated IGRT in patients with bone metastases 
in various locations. Patients treated with single-dose 
IGRT (≥24 Gy) had a signiﬁ cantly better 3-year actuarial 
local progression-free survival than those treated with 
hypofractionated IGRT (88% vs 17%; p=0·001), which was 
also shown with a Cox regression analysis (p=0·008). In 
another study,35 metastasectomy with curettage and local 
stabilisation was compared with no surgical treatment of 
solitary bone metastases in various locations. 
A signiﬁ cantly higher proportion of patients who 
underwent surgical intervention achieved 5-year cancer-
speciﬁ c survival compared with those with no intervention 
(36% vs 8%; p=0·0066). Findings from a multivariate 
analysis of cancer-speciﬁ c survival, adjusting for previous 
nephrectomy, sex, and age, still favoured metastasectomy 
with curettage and intramedullary stabilisation compared 
with no surgical treatment (p=0·018). A third study34 
compared the eﬃ  cacy and durability of pain relief 
between single-dose SBRT and CRT in patients with bone 
metastases to the spinal column (C1 sacrum); no 
signiﬁ cant diﬀ erence between pain objective responses 
(p=0·67), time to pain relief (p=0·29), or duration of pain 
relief (p=0·095) was found (table 2).
Local therapies for brain metastases
Two studies on brain metastases from renal cell 
carcinoma were included (table 2). One study36 compared 
SRS, WBRT, and the combination of both SRS and 
WBRT. All patients in the WBRT and combination 
groups had at least two brain metastases, whereas such 
patients accounted for 17·6% of the SRS group. Each 
group was further subdivided into recursive partitioning 
analysis (RPA), a statistical method for undertaking 
multivariate analysis, based on a decision tree with 
dichotomous variables classes I–III (I=favourable, 
II=moderate, and III=poor patient status). A signiﬁ cant 
Figure 2: Forest plot of hazard ratios for overall survival or cancer-speciﬁ c survival in studies comparing 
incomplete or no metastasectomy versus complete metastasectomy
*Variance method, ﬁ xed-eﬀ ects model. †Cancer-speciﬁ c survival.
Alt (2011)12 0·9594           0·1379 2·61 (1·99–3·42)
Pretalia (2010)†24 0·5365 0·2306 1·71 (1·09–2·69)
Staehler (2010)25 0·802 0·3825 2·23 (1·05–4·72)
Staehler (2009)26 0·7608 0·201 2·14 (1·44–3·17)
Eggener (2008)27 0·9933 0·2606 2·70 (1·62–4·50)
Kwak (2007)30 0·9439 0·3826 2·57 (1·21–5·44)
Lee (2006)†32 1·2442 0·5171 3·47 (1·26–9·56)
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improvement in 2-year intracerebral control was found 
when adding WBRT to SRS compared with SRS alone 
(p=0·032), but no such diﬀ erence was noted for 2-year 
overall survival (p=0·703); both were superior to WBRT 
alone in the general study population (all p<0·001) and 
in the RPA subgroup analyses (all p<0·001). In a 
subgroup analysis of RPA class I, the comparison of SRS 
with SRS plus WBRT revealed signiﬁ cantly better 2-year 
overall survival and intracerebral control for the 
combination group (p<0·001 for both). The other study37 
compared fractionated stereotactic radiotherapy (FSRT) 
with metastasectomy plus CRT, or CRT alone. Only six 
(55%) patients after metastasectomy plus CRT and four 
patients (33%) after CRT were followed up with imaging. 
Several of the patients in all groups underwent alternative 
surgical and non-surgical treatments after initial 
treatment. Survival at 1, 2, and 3 years were 90%, 54%, 
and 41% for FSRT, 64%, 27%, and 9% for metastasectomy 
plus CRT, and 25%, 17% and 8% for CRT, respectively. 
No p value was reported for survival. FSRT did not have a 
signiﬁ cantly better 2-year local control compared with 
metastasectomy plus CRT (p=0·61); whether FSRT gave 
signiﬁ cantly better 2-year local control than CRT alone 
was not reported.
Risk of bias and confounding
Figure 3 summarises the risk of bias and confounding 
for all included studies. All studies were retrospective 
and non-randomised, leading to the high risk of bias 
associated with non-randomisation, patient attrition, 
and selective reporting. With the exception of one 
study,12 all studies were substantially underpowered. 
Regarding confounding, about half of studies reported 
adequate data on age and sex. Systemic treatment type 
and the frequency of their use were heterogeneous. 
Although performance status was included in the 
baseline characteristics in most studies, there was 
heterogeneity in performance status classiﬁ cation. 
There was a moderate-to-high risk of confounding 
regarding previous treatment, tumour histology, grade, 
and size or volume of metastases, especially in studies 
on local treatments of bone and brain metastases.33–37 
Regarding diﬀ erent sites treated in the same study, 
there was generally a moderate-to-high risk of 
confounding, especially for studies pertaining to 
treatment of metastases at various sites,12,27,30–32 because 
it was often unclear if these confounders were adjusted. 
Evidence quality was not assessed by GRADE because 
of the nature of the included studies (ie, retrospective 
comparative studies), and the high risk of bias across 
the studies.
Discussion
The results of this systematic review suggest a survival 
beneﬁ t with complete metastasectomy versus either 
incomplete or no metastasectomy for renal cell carcinoma 
metastases to parenchymal organs. There was also some 
evidence in favour of local treatment in terms of symptom 
control, such as pain relief in patients with bone 
metastases. The great variation in type and distribution of 
systemic treatment, and its response being reported in 
only a subset of studies, prevents any conclusion on the 
role and eﬀ ect of targeted treatment in the setting of 
complete metastasectomy. However, in a non-comparative 
report,38 most patients who had a complete response after 
a combination of targeted treatment and local treatment 
stopped systemic treatment. After a median follow-up of 
10·7 months (range 0·3–54·0), 48% of patients had still 
not experienced disease progression; these data suggest 
that local treatment might have a role in delaying return 
to systemic treatment and associated toxicity.
The main strength of this Review is its robust 
methodology, which adheres to strict criteria that are 
rigorous, transparent, and reproducible. We have described 
the best available contemporary evidence base, from which 
Figure 3: Risk of bias and confounding assessment summary
Green circle=low risk of bias and confounding. Red circle=high risk of bias and confounding. Yellow circle=unclear 
risk of bias and confounding.
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some conclusions can be made, and identiﬁ ed knowledge 
gaps that can only be addressed through well-designed, 
prospective comparative studies.
However, there are several limitations. All included 
studies were retrospective comparative studies, 
involving small numbers of patients; there were no 
randomised controlled trials or prospective non-
randomised comparative studies. There were generally 
high risks of bias across all included studies and across 
most domains, including a substantial risk of 
confounding. As a result, only a narrative synthesis of 
the evidence was presented; a meta-analysis was not 
possible because of the aforementioned limitations. 
Additionally, the search was limited to studies published 
from 2000 onwards; earlier publications might have 
been missed, although a scoping exercise of the available 
published work before 2000 did not reveal any 
randomised controlled trials. The generally poor quality 
of the evidence base imply that there is signiﬁ cant 
uncertainty regarding our ﬁ ndings, and, therefore, 
caution is needed in their interpretation. For instance, 
we cannot rule out that the reported beneﬁ t is largely 
due to an indication bias on the basis of diﬀ erences in 
tumour aggressiveness. Potentially, patients with 
oligometastasis and long metachronous intervals are 
more likely to be candidates for metastasectomy, 
whereas those with a high-volume metastasis, rapid 
progression, and reduced performance status often do 
not undergo resection. Several non-comparative studies 
suggest that the disease dynamic might be more 
important than any intervention. Low tumour grade39 
and long metachronous intervals with repeat resection40 
are associated with long survival. No reliable data exist 
on the proportion of patients with metastatic renal cell 
carcinoma who would be eligible for local treatment of 
their metastases. At diagnosis, 57–65% of patients with 
metastatic renal cell carcinoma have single sites; the 
percentage of patients with single sites increases with 
age.10 Estimates suggest that 25% of patients with 
metachronous metastasis might be candidates for local 
treatment.12 For synchronous metastatic disease, this 
proportion may be less than 10%.41 The investigators of 
most studies identiﬁ ed in this systematic review 
acknowledge that patient selection for local treatment of 
metastases is complex because of the heterogeneous 
course of metastatic renal cell carcinoma, surgical 
resectability, and anatomical access.
There is general consensus that several clinical and 
pathological factors, such as performance status, disease-
free interval, burden and site of metastases, histological 
subtype, and Fuhrman grade aﬀ ect the prognosis and 
management of metastatic renal cell carcinoma to a large 
extent.42 Most of the data on metastasectomy exist for 
patients with clear-cell renal cell carcinoma; little is known 
for other subtypes such as papillary renal cell carcinoma.43 
Accurate information on prognosis is of utmost 
importance for treatment decisions. The Memorial Sloan 
Kettering Cancer Centre (MSKCC) risk score is one of the 
most commonly used prognostic models and establishes 
which patients have favourable, intermediate, and poor 
risks using Karnofsky performance status, the time from 
diagnosis to treatment, and serum haemoglobin, calcium, 
and lactate dehydrogenase concentrations.44 Surprisingly, 
we identiﬁ ed only two studies that reported the MSKCC 
score.25,27 For patients receiving targeted treatment, the 
MSKCC score and the validated Database Consortium 
model share concordance indices of 0·66–0·65 to assess 
prognosis.8,45,46 In one of the studies included in the 
systematic review, a more favourable risk category and 
metastasectomy were each independently associated with 
better survival.27 However, this may be because, with a 
median survival of 6 months for poor-risk patients, these 
patients do not live long enough to derive beneﬁ t from 
metastasectomy. Other more site-speciﬁ c clinical factors 
that might have prognostic value for local treatment of 
metastases are recognised, and were partly discussed in 
the studies included in the systematic review.
Most data exist for lung metastases, which are the most 
common metastases from renal cell carcinoma. Large, 
non-comparative case series not included in the 
systematic review reported 5-year survival of 37–54% for 
completely resected solitary or oligometastatic pulmonary 
metastases.47–53 Multivariate analyses consistently 
identiﬁ ed a pattern of prognostic factors (panel). Having 
a higher number of removed pulmonary metastases,12,51,54 
concomitant mediastinal nodal metastasis,47,51–53 or 
incomplete resection12,48,51–54 was associated with poorer 
5-year survival of 0–24·4%. Additionally, a short disease-
free interval after nephrectomy or synchronous 
metastasis was associated with a poor outcome, 48,51,52,54 as 
was size of lung metastases.47,52,55 A lung-speciﬁ c 
prognostic score including these factors has been 
developed from 200 consecutive patients with pulmonary 
metastases; this score needs external validation.56
Interpretation of the identiﬁ ed studies for bone and 
brain metastases that assessed radiotherapy or compared 
radiotherapy to surgery is problematic. During the long 
study periods of 6–15 years represented by the included 
studies, substantial advances were made in radiotherapy, 
including changes in dosage and modalities. Additionally, 
location, size, and soft-tissue involvement of metastases 
varied substantially between studies, and were 
inconsistently reported, which prevented a direct 
comparison of results. Although ﬁ ndings from this 
systematic review suggest prolonged disease-free survival 
after SBRT or metastasectomy of single and multiple bone 
metastases, no recommendations can be made as to the 
best treatment modality. However, ﬁ ndings from a 
randomised controlled trial in patients with bone 
metastasis from various cancers, including renal cell 
carcinoma, showed that immediate decompressive surgery 
and postoperative radiotherapy is superior to radiotherapy 
alone for patients with spinal cord compression.57 Findings 
from a further small non-comparative study suggested 
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SRS reduced progression and pain in patients with renal 
cell carcinoma spinal lesions.58 In addition to general 
prognostic factors, peripheral location of bone metastases 
is a favourable factor.12,59–62
Only two studies were identiﬁ ed that compared diﬀ erent 
radiotherapy modalities, including in combination with 
surgery, for brain metastases from renal cell carcinoma. 
Thus, recommendation of a speciﬁ c treatment modality is 
not possible. However, ﬁ ndings from additional studies 
on non-renal cell carcinoma brain metastases suggest a 
prognostic score-related approach. With SRS, craniotomy 
is now not frequently used except for brain metastases 
larger than 3 cm in size, and rapidly symptomatic lesions 
with midline shift.63,64 Brain metastases from renal cell 
carcinoma were mostly assessed collectively with cerebral 
lesions from other malignancies. Recommendations for 
radiotherapy follow the Radiation Therapy Oncology 
Group RPA developed from brain metastases irrespective 
of the primary tumour site (RPA class I: Karnofsky 
performance status ≥70, age <65 years, primary tumour 
controlled, no extracranial sites; class II: Karnofsky 
performance status ≥70 with absence of at least one of the 
other factors; class III: Karnofsky performance status 
<70).65 About three-quarters of patients belong to RPA 
class II.63,66 In a retrospective non-comparative study, 
85 patients with renal cell carcinoma with brain metastases 
who underwent SRS were assessed.63 Median metastatic 
volume was 1·2 cm (range 0·1–14·2) and 65% of patients 
had multiple cerebral metastases. After SRS, median 
overall survival was 11 months with 94% of patients 
achieving local control. Most patients (78%) died of 
extracranial progression. Median overall survival was 
24·2 months for RPA class I, 9·2 months for class II, and 
7·5 months for class III. In a study of 4295 patients with 
brain metastases from renal cell carcinoma, Karnofsky 
performance status and number of brain metastases were 
identiﬁ ed as signiﬁ cant prognostic factors.67 Patients with 
a Karnofsky performance status of 90–100 and one brain 
lesion had a median overall survival of 14·8 months 
(95% CI 12·9–17·1) versus 3·3 months (3·0–3·8) for 
those with a Karnofsky performance status less than 70 and 
more than three metastases. Present data suggest that 
WBRT is adequate for patients with poor performance 
who need palliative treatment for multiple lesions. SRS 
can provide eﬀ ective local control comparable to surgery, 
even for multiple and recurrent metastases, and is 
recommended for patients with RPA classes I and II.68
For liver and pancreatic metastases, a potential beneﬁ t 
needs to be balanced against morbidity and mortality of 
local treatment. In the study included in this systematic 
review, liver metastasectomy was associated with signiﬁ cant 
morbidity in 20·1% of patients,25 with no beneﬁ t for those 
with high-grade renal cell carcinoma and synchronous 
metastases. By contrast, a non-comparative retrospective 
analysis of 43 patients reported low morbidity and mortality, 
resulting in a 3-year overall survival of 62·1% and a median 
recurrence-free survival of 15·5 months.69 Additionally, 
ablative techniques and SRS have resulted in eﬀ ective local 
control of small liver metastases.70–72
Cumulative data suggest that pancreatic metastasectomy 
might be beneﬁ cial in patients with good performance 
status and one metastatic site.73 However, 2·8% in-
hospital mortality after extensive surgery, done as 
pancreaticoduodenectomy in 35·8% of patients and total 
pancreatectomy in 19·9% of patients, suggests that 
morbidity and mortality might outweigh the potential 
beneﬁ t. In view of the overall low quality of the data, and 
the substantial surgical morbidity, patients with a short 
interval to pancreatic metastasis after nephrectomy may 
be best treated with systemic therapy.
Despite lymph nodes being the third metastatic site in 
21·8% of patients,10 we identiﬁ ed few studies reporting 
Panel: General and site-speciﬁ c factors for lung, bone, and brain associated with a 
favourable outcome after local treatment of metastases from renal cell carcinoma
General*
Patient factors
• Good performance status (Karnofsky performance status, Eastern Cooperative 
Oncology Group performance status, WHO)
• Memorial Sloan Kettering Cancer Center or Heng favourable and intermediate risk
Extent of disease
• Solitary or oligometastatic lesions
• Single organ site
• Absence of nodal metastases
Course of disease
• Metachronous metastasis
• Disease-free interval of over 2 years
• Absence of progression to treatment
Tumour biology
• Absence of sarcomatoid component
• Clear-cell subtype




• Fewer than seven metastases
• Absence of mediastinal lymph node metastases
• Metastases less than 4 cm in diameter
• Unilateral lung involvement
Bone
• Peripheral location of metastases
Brain
• Radiation Therapy Oncology Group recursive partitioning analysis class I:
• Karnofsky performance status greater than 70
• Age younger than 65 years
• Absence of extracranial metastatic sites
• Control of the primary tumour
• Karnofsky performance status 90–100 and single lesion
*Other sites follow the general factors.
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on only subgroups of patients who underwent nodal 
metastasectomy, compared with either no or incomplete 
resection. Isolated metachronous nodal metastases are 
rare and most patients harbour additional extensive 
metastatic disease at multiple sites,74 precluding complete 
metastasectomy, which might explain the low number of 
comparative retrospective studies retrieved.
In conclusion, to the best of our knowledge, this is the 
ﬁ rst systematic review to identify the evidence base 
regarding the role of local treatment of metastases from 
renal cell carcinoma. The results consistently point 
towards a beneﬁ t of complete metastasectomy in terms 
of overall survival and cancer-speciﬁ c survival. With the 
exception of brain and possibly bone metastases, 
metastasectomy remains by default the most appropriate 
local treatment for most sites. There is also some 
evidence for local control beneﬁ ts such as pain relief for 
bone metastases. Because of the poor quality of included 
studies, whether the reported survival beneﬁ t is a 
consequence of local treatment, or a selection bias of 
those patients whose tumour biology allowed them to 
proceed to metastasectomy, or both, remains unresolved. 
Future prospective studies, preferably with randomised 
design and larger populations, are needed to increase 
the quality of evidence regarding local treatment of 
metastases from renal cell carcinoma. Finally, from a 
clinical perspective, the possible survival and symptom 
control beneﬁ ts in patients with metastatic renal cell 
carcinoma who are eligible for local treatment should be 
discussed in multidisciplinary boards to tailor 
treatments individually. Despite prognostic factors 
consistently being associated with a favourable outcome 
after metastasectomy, no general treatment guideline 
can be given, because of the large uncertainties that 
exist in the evidence base. Careful patient selection is of 
paramount importance, and the decision to resect 
metastases has to be taken for each site, and on a case-
by-case basis. Performance status, risk proﬁ les, patient 
preference, and alternative techniques to achieve local 
control, such as SRS or ablation, must be considered. 
There might also be a role for local treatment of 
metastases in terms of delaying systemic treatment and 
associated toxicity.
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